Trial
NCT02539017
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
Phase IIWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Collaborators
—
Condition
Triple Negative Breast Neoplasms
Intervention
Chemo
Why stopped
because of safety problem, this trial was stopped in the hospital
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-08-10